A Review Focused on Exerkines in Extracellular Vesicles Generated by Muscle Tissue

Key Takeaways

• Exercise releases muscle-derived exosomes carrying bioactive cargo.
• Exosomal cargo modulates stem cell activation and inflammation.
• Heterogeneous EVs reflect tissue health, aging, insulin resistance.
• Engineered exosomes show promise for musculoskeletal therapies.
• Standardization and regulation remain major hurdles.

Pulse Analysis

The concept of exerkines expands the classic view of exercise biology beyond soluble myokines, positioning extracellular vesicles as dynamic messengers that encode the metabolic state of contracting muscle. Recent proteomic and RNA‑sequencing studies reveal that a single bout of endurance or resistance training reshapes the exosomal payload, enriching factors that trigger satellite‑cell proliferation, suppress chronic inflammation, and enhance mitochondrial function in remote organs. This mechanistic insight explains why regular physical activity confers protection against metabolic syndrome and age‑related muscle loss.

Biotech firms are now exploring engineered EVs as a platform for targeted delivery of therapeutic RNAs and proteins to damaged musculoskeletal tissue. By mimicking the natural exerkine signature, these nanocarriers could accelerate tissue repair, reduce reliance on invasive stem‑cell transplants, and serve as minimally invasive biomarkers for disease monitoring. Early preclinical models demonstrate improved muscle regeneration and insulin sensitivity after administration of muscle‑derived exosome mimetics, sparking interest from venture capital and pharmaceutical pipelines.

Despite the promise, the field grapples with fragmented isolation protocols, variable dosing metrics, and an absence of FDA‑aligned guidelines. Standardizing vesicle characterization, scaling GMP‑compatible production, and establishing safety benchmarks are essential before clinical translation. As regulatory bodies draft frameworks for extracellular vesicle therapeutics, stakeholders must align scientific rigor with commercial viability to unlock the full potential of exerkine‑based interventions.